MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015)

Conditions:   Arteriosclerosis;   Hypercholesterolaemia Interventions:   Drug: MK-0616;   Drug: Placebo Sponsor:   Merck Sharp & Dohme LLC Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials